Title:
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC).
Protocol Number:
J1225
Phase:
Phase II
Physician:
Christine Hann
Purpose:
NULL
Eligibility:
NULL
Treatment:
NULL
Population:
Adult
Last Update
05/25/2013 04:02 AM
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts